Breaking Finance News

A statement released earlier today by Canaccord Genuity about Shield Therapeutics Plc (LON:STX) bumps the target price to 241.00GBX

Only yesterday Shield Therapeutics Plc (LON:STX) traded 1.92% higher at 159.00GBX. Shield Therapeutics Plc’s 50-day average is 156.35GBX and its 200-day average is 166.01GBX. The last stock close is down 4.22% relative to the 200-day average, compared with the S&P 500 Index which has fallen -0.01% over the same time period. 45,024 shares of Shield Therapeutics Plc traded, up from ann average trading volume of 2,963.

Indicating a possible upside of 0.52%, Canaccord Genuity bumped the price target of Shield Therapeutics Plc (LON:STX) to 241GBX

On Thursday August 11 2016, Canaccord Genuity released a statement about Shield Therapeutics Plc(LON:STX) maintained the target price at 235.00GBX that suggested an upside of 0.49%.

Performance Graphic:

Shield Therapeutics Plc (LON:STX)

Shield Therapeutics Plc has a one-year low of 147.00GBX and a 52 week high of 190.00GBX and has a total market value of 0.0 GBX.

More About Shield Therapeutics Plc (LON:STX)

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), and is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.